Gland Pharma Ltd News Today

The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.

Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.

Here are some of the stocks that may see significant price movement today: Tata Chemicals, Power Grid, Welspun Enterprises, etc.

EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) increased by 1% YoY to ₹360 crore, compared to ₹356.4 crore in the previous year.

Sintilimab is marketed in China as TYVYT (sintilimab injectable) and was co-developed by Innovent and Eli Lilly.

Here are some of the stocks that may see significant price movement today: Power Mech, IndiGo, NHPC, Gland Pharma, etc.